Top

American Journal of Clinical Dermatology

Published in:

Open Access 01-11-2021 | Vulgar Psoriasis | Current Opinion

Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments

Authors: Christine Blome, Matthias Augustin, Toni Maria Klein

Published in: American Journal of Clinical Dermatology | Issue 6/2021

Abstract

Nail involvement is frequent in people with psoriasis. It can considerably impair health-related quality of life (HRQoL) beyond the impairments due to other psoriasis symptoms, for example, because patients feel ashamed of visible nail defects or because of the functional impairment in manual activities and walking. In clinical trials on nail psoriasis, it is therefore crucial to assess whether the treatment reduces HRQoL impairments that are specific to nail psoriasis. For this purpose, two validated patient questionnaires are available, the Nail Psoriasis Quality of Life Scale (NPQ10) and the Nail Assessment in Psoriasis and Psoriatic Arthritis–Quality of Life (NAPPA-QOL). The ten-item NPQ10 has the advantage of being short and thus quick to administer. The 20-item NAPPA-QOL, in contrast, assesses the different dimensions of HRQoL which is considered a multi-dimensional construct. Yet most randomized controlled trials on nail psoriasis do not evaluate HRQoL improvement. If they do, a number of different instruments are used, most of which are not nail specific. This makes comparison of trial outcomes difficult. Harmonizing the measurement of HRQoL in future clinical trials on nail psoriasis would improve comparability across studies and would also enhance the reliability of meta-analyses.

Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. https://doi.org/10.1186/s12895-020-00099-7.CrossRefPubMedPubMedCentral

Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580–5. https://doi.org/10.1111/j.1365-2133.2010.09831.x.CrossRefPubMed

Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F. Epidemiology of psoriasis and psoriatic arthritis in italy-a systematic review. Curr Rheumatol Rep. 2018;20(7):43. https://doi.org/10.1007/s11926-018-0753-1.CrossRefPubMed

Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–8. https://doi.org/10.1111/bjd.13272.CrossRefPubMed

Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011;2:1–6. https://doi.org/10.2147/PROM.S14861.CrossRefPubMed

Bardazzi F, Michela S, Francesca B, Michela M, Bianca MP, Aurora A. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol. 2019;99(6):516–23. https://doi.org/10.2340/00015555-3098.CrossRefPubMed

Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K, Augustin M. Patient-relevant needs and treatment goals in nail psoriasis. Qual Life Res. 2016;25(5):1179–88. https://doi.org/10.1007/s11136-015-1136-y.CrossRefPubMed

van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life. Dermatology. 2014;229(2):76–82. https://doi.org/10.1159/000360696.CrossRefPubMed

Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh JA. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19262.CrossRefPubMedPubMedCentral

10.

Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatol Treat. 2021;1:1–9. https://doi.org/10.1080/09546634.2021.1892024.CrossRef

11.

Zhang X, Xie B, He Y. Efficacy of systemic treatments of nail psoriasis: a systemic literature review and meta-analysis. Front Med (Lausanne). 2021;8: 620562. https://doi.org/10.3389/fmed.2021.620562.CrossRefPubMedPubMedCentral

12.

Forestier B, Anthoine E, Reguiai Z, Fohrer C, Blanchin M. A systematic review of dimensions evaluating patient experience in chronic illness. Health Qual Life Outcomes. 2019;17(1):19. https://doi.org/10.1186/s12955-019-1084-2.CrossRefPubMedPubMedCentral

13.

Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HC. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49. https://doi.org/10.1007/s11136-010-9606-8.CrossRefPubMedPubMedCentral

14.

Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–7. https://doi.org/10.1111/jdv.12106.CrossRefPubMed

15.

Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157:238–44. https://doi.org/10.1159/000250839.CrossRefPubMed

16.

Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–11. https://doi.org/10.1067/s0190-9622(03)00910-1.CrossRefPubMed

17.

Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;170:591–8. https://doi.org/10.1111/bjd.12664.CrossRefPubMed

18.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x.CrossRefPubMed

19.

Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, Piguet V. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2017;176(3):577–93. https://doi.org/10.1111/bjd.14788.CrossRefPubMed

20.

McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CE, Van Assche D. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003;149(2):323–31. https://doi.org/10.1046/j.1365-2133.2003.05492.x.CrossRefPubMed

21.

Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of Nail Psoriasis Quality of Life Scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22–7. https://doi.org/10.1111/j.1468-3083.2009.03344.x.CrossRefPubMed

22.

Goldust M, Raghifar R. Clinical trial study in the treatment of nail psoriasis with pulsed dye laser. J Cosmet Laser Ther. 2013. https://doi.org/10.3109/14764172.2013.854627.CrossRefPubMed

23.

Poulin Y, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC. Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH. J Eur Acad Dermatol Venereol. 2014;28(7):882–90. https://doi.org/10.1111/jdv.12198.CrossRefPubMed

24.

Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29(2):353–60. https://doi.org/10.1111/jdv.12553.CrossRefPubMed

25.

Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, Molta CT, Boggs R. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23(8):896–904. https://doi.org/10.1111/j.1468-3083.2009.03211.x.CrossRefPubMed

26.

Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954–66. https://doi.org/10.1111/bjd.17351.CrossRefPubMed

27.

Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA. Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78(1):90–99.e1. https://doi.org/10.1016/j.jaad.2017.08.029

28.

Elewski BE, Baker CS, Crowley JJ, Poulin Y, Okun MM, Calimlim B, Geng Z, Reyes Servin O, Rich PA. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2019;33(11):2168–78. https://doi.org/10.1111/jdv.15793.CrossRefPubMedPubMedCentral

29.

Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–45. https://doi.org/10.2165/11538370-000000000-00000.CrossRefPubMed

30.

Busard CI, Nolte JYC, Pasch MC, Spuls PI. Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review. Br J Dermatol. 2018;178(3):640–9. https://doi.org/10.1111/bjd.15831.CrossRefPubMed

31.

Perez-Chada LM, Merola JF, Armstrong AW, Garg A, Latella J, Gottlieb AB. Report from the International Dermatology Outcome Measures Initiative. J Investig Dermatol Symp Proc. 2020;20(1):S80–3. https://doi.org/10.1016/j.jisp.2020.05.004.CrossRefPubMed

32.

Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW. Identifying a core domain set to assess psoriasis in clinical trials. JAMA Dermatol. 2018;154(10):1137–44. https://doi.org/10.1001/jamadermatol.2018.1165.CrossRefPubMedPubMedCentral

33.

Augustin M, Ogilvie A. Methods of outcomes measurement in nail psoriasis. Dermatology. 2010;221(Suppl 1):23–8. https://doi.org/10.1159/000316177.CrossRefPubMed

34.

Mokkink LB, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, de Vet HCW, Terwee CB. COSMIN study design checklist for Patient-reported outcome measurement instruments. 2019. https://www.cosmin.nl/wp-content/uploads/COSMIN-study-designing-checklist_final.pdf. Accessed 2 June 2021.

Title: Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments
Authors: Christine Blome
Matthias Augustin
Toni Maria Klein
Publication date: 01-11-2021
Publisher: Springer International Publishing
Keywords: Vulgar Psoriasis
Psoriatic Arthritis
Secukinumab
Published in: American Journal of Clinical Dermatology / Issue 6/2021
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-021-00622-7

At a glance: The STEP trials

Springer Medicine

Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts

Ceramides in Skin Health and Disease: An Update

Acknowledgement to Referees

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons